Tissue Diagnostic Market Report 2025

This Tissue Diagnostic report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The tissue diagnostic market size has grown rapidly in recent years. It will grow from $5.77 billion in 2024 to $6.44 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to aging population, cancer prevalence, technological advancements, increased disease awareness, pathology workflow efficiency.

The tissue diagnostic market size is expected to see rapid growth in the next few years. It will grow to $10.67 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to personalized medicine growth, rise of liquid biopsies, ai and machine learning adoption, telepathology expansion, minimally invasive techniques. Major trends in the forecast period include digital pathology, artificial intelligence (ai), telepathology services, multiplex staining and imaging, integration of genomic data.

The increasing incidence of cancer is expected to drive the growth of the tissue diagnostic market in the coming years. Cancer begins when genetic changes cause cells to grow uncontrollably, destroying body tissue and forming a mass known as a tumor, which can be either cancerous or benign. Various factors, including genetic mutations, carcinogens, smoking, obesity, radiation, and hormones, can lead to the development of cancer. As cancer cases rise, the demand for diagnostic procedures like tissue diagnostics will grow, as these are essential in determining the disease's progression. For example, in February 2024, the World Health Organization, a Switzerland-based United Nations agency, projected that new cancer cases would rise to over 35 million by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Thus, the rising cancer incidence is fueling the expansion of the tissue diagnostic market.

The increasing healthcare expenditure is expected to drive the growth of the tissue diagnostic market. Healthcare expenditure refers to the total amount of money spent on healthcare services, treatments, and products over a certain period, either at the national or individual level. This spending supports the development, accessibility, and utilization of advanced diagnostic technologies, research, and medical infrastructure, including tissue diagnostics. For example, in July 2024, the American Medical Association, a US-based nonprofit organization, reported that from 2012 to 2022, the average annual growth rate for prescription drugs was the highest at 4.7%, compared to 4.4% for hospital care and 4.2% for physician services. This increase in healthcare spending helps foster advancements in diagnostic technologies, driving the growth of the tissue diagnostic market.

Product innovation is a growing trend in the tissue diagnostic market, with companies introducing advanced products and solutions that can collect multiple sample types, test multiple samples simultaneously, automate lab operations, and make diagnostics more accessible. Leading players are focusing on developing automated tissue diagnostic systems to gain a competitive advantage and boost revenue. For instance, in June 2022, Roche, a Switzerland-based healthcare company, launched the BenchMark ULTRA PLUS system for cancer diagnostics. This tissue staining system features optimized workflow, enhanced testing efficiency, and sustainable environmental features, allowing pathologists to deliver high-quality, timely results to doctors and patients. Key innovations in the system include intuitive software, remote monitoring capabilities, an integrated touchscreen for a better user experience, and environmentally sustainable waste management and packaging.

The technological advancements, particularly the integration of artificial intelligence (AI), are influencing the tissue diagnostic market. AI is employed to analyze medical images and pathological data, enhancing the accuracy and efficiency of disease detection and classification. For instance, in 2023, Qritive introduced the Qai Prostate, an AI-powered prostate cancer detection tool, providing pathologists with advanced capabilities for detecting and classifying malignant and benign tumor locations in biopsy tissue samples. This integration of AI represents a strategic move to improve precision in cancer diagnosis and treatment within the tissue diagnostic market.

In February 2022, Labcorp's acquisition of Personal Genome Diagnostics (PGDx) for $575 million stands out. This move strengthens Labcorp's next-generation sequencing-based genomic profiling capabilities and enhances existing liquid biopsy capabilities, reflecting the industry's commitment to advancing cancer genomics.

Major companies operating in the tissue diagnostic market include F. Hoffmann-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Agilent Technologies Inc., Merck KGaA, BioGenex Laboratories, Sakura Finetek Co. Ltd., Philips Healthcare NV, Bio-Rad Laboratories, Ventana Medical Systems Inc., Hologic Inc., Becton Dickinson and Company, Sysmex Corporation, Cell Signaling Technology Inc., Enzo Life Sciences Inc., Epitomics Inc., Fluidigm Corporation, GE Healthcare Technologies Inc., Genomic Health Inc., Illumina Inc., Leica Microsystems GmbH, Menarini Diagnostics S.r.l, Myriad Genetics Inc., NanoString Technologies Inc., PerkinElmer Inc., QIAGEN N.V., Siemens Healthineers AG, Zeiss Group AG, CytomX Therapeutics Inc.

North America was the largest region in the tissue diagnostic market in 2024. The regions covered in the global tissue diagnostic industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the tissue diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Tissue diagnostic refers to a medical procedure that uses instruments to remove and stain tissue that must be sent to a laboratory or pathology department for documentation of what was excised for patient care (for tissue diagnostics). This offers measurements and descriptions, including any abnormalities, and an interpretation (or diagnosis) of health or disease status, under applicable legislation.

The main types of products in tissue diagnostic are consumables, antibodies, kits, reagents, probes, instrument, slide staining system, scanner and tissue processing system. The antibodies are used for the detection of infections, recognition of allergies, and the measurement of hormones and other biological markers in the blood in tissue diagnostics. The technologies used in tissue diagnostic are immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology and workflow management and special staining to detect diseases such as breast cancer, gastric cancer, lymphoma, prostate cancer and non-small cell lung cancer (NSCLC). Tissue diagnostic is mostly used in hospitals, research laboratories, pharmaceutical companies, and contract research organizations.

The tissue diagnostic market research report is one of a series of new reports that provides tissue diagnostic market statistics, including tissue diagnostic industry global market size, regional shares, competitors with a tissue diagnostic market share, detailed tissue diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the tissue diagnostic industry. This tissue diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tissue diagnostic market includes revenues earned by entities by consumables and instruments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.